Earnings Preview: Humacyte
Portfolio Pulse from Benzinga Insights
Humacyte (NASDAQ:HUMA) is scheduled to release its quarterly earnings report on Friday, 2024-03-22, with an estimated EPS of $-0.24. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Humacyte's stock price has shown sensitivity to both earnings outcomes and forward guidance. The stock was trading at $3.51 as of March 20, reflecting a 24.4% increase over the last 52 weeks.
March 21, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Humacyte is expected to report an EPS of $-0.24 for the upcoming quarter. Historical data shows stock price sensitivity to earnings outcomes and guidance. Shares have risen 24.4% over the past year.
Given Humacyte's historical performance, where stock price has shown to react positively or negatively to earnings outcomes and forward guidance, the upcoming earnings report is crucial. The anticipation of beating the EPS estimate and providing positive future guidance could lead to a positive short-term impact on HUMA's stock price, especially considering the stock's positive trajectory over the last year.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100